Anderson Hoagland & Co. lowered its stake in Celgene Co. (NASDAQ:CELG) by 22.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,576 shares of the biopharmaceutical company’s stock after selling 3,724 shares during the period. Anderson Hoagland & Co.’s holdings in Celgene were worth $1,180,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital Management Corp VA bought a new position in shares of Celgene in the first quarter valued at $10,955,000. Canyon Capital Advisors LLC acquired a new stake in Celgene during the 1st quarter valued at $119,226,000. Tibra Equities Europe Ltd acquired a new stake in Celgene during the 1st quarter valued at $6,396,000. Ruffer LLP acquired a new stake in Celgene during the 1st quarter valued at $226,613,000. Finally, Global Trust Asset Management LLC raised its stake in Celgene by 212.3% during the 1st quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 3,098 shares during the period. 74.87% of the stock is currently owned by institutional investors.
Shares of Celgene stock traded up $0.35 on Tuesday, hitting $89.82. 5,349,129 shares of the company traded hands, compared to its average volume of 8,433,500. The stock’s 50-day moving average is $94.11. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $98.97. The company has a market cap of $62.90 billion, a P/E ratio of 11.80, a PEG ratio of 0.43 and a beta of 1.45.
Several brokerages have issued reports on CELG. William Blair began coverage on shares of Q2 in a research note on Monday, April 1st. They set an “outperform” rating and a $69.71 target price on the stock. BidaskClub raised shares of Zillow Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Barclays set a $24.00 target price on shares of Orion Engineered Carbons and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Atlantic Securities downgraded shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price on the stock. in a research note on Monday, April 1st. Two investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $95.22.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: What can cause a stock to outperform?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.